Numerous infections are linked to Pseudomonas aeruginosa. It is one of the major medical concerns because of virulence and antibiotic resistance. Antibiotic encapsulation in liposomes is a good strategy for controlling infections caused by this microorganism. Evaluation of anti-Pseudomonas aeruginosa effect of liposomal form of Imipenem/Cilastatin in vitro condition. By using the disk agar diffusion technique, the isolates’ pattern of antibiotic resistance was identified. The antibiotic was placed into the nanoliposome after it had been made using the thin layer and ethanol injection techniques. SEM and DLS were used to determine the size, shape, and zeta potential of the encapsulated drug form and the empty nanoliposome. Additionally, Imipenem/Cilastatin encapsulation in nanoliposomes was studied using FT-IR spectroscopy. In the microbial assay experiments the MIC, MBC and MBEC of liposomal and free drug forms were determined. The nanoparticles were spherical, with a diameter ranging from 30 to 39 nm, and the EE% in the thin layer and ethanol injection procedures were 97 and 98, respectively. Imipenem/Cilastatin nanoliposomes showed peaks at 3009 cm⁻¹ and 1650 cm⁻¹, demonstrating the thermodynamic stability for the chemical structure of the drug enclosed and validating the encapsulation of antibiotic in the nanoliposomes. When compared to free drug forms, nanoliposomes had lower MIC and MBC values in the majority of the isolates and had a greater ability to eradicate the biofilm formation. It was shown that the two nanoliposome preparation techniques were more efficient in 80% of the isolates, which had outcomes that were consistent with those of numerous other investigations. Overall, we demonstrated that the antibacterial activity of nanoliposomes was higher than that of the free drug form based on the evaluation of their MIC and MBC. Pharmaceutical nanoliposome techniques provide an excellent future perspective on how to manage microbial infections that are resistant to antibiotics.

Graphical Abstract

中文翻译：

---

亚胺培南/西司他丁纳米脂质体对临床铜绿假单胞菌的抗菌膜和生长抑制作用增强

许多感染与铜绿假单胞菌有关。由于毒力和抗生素耐药性，它是主要的医学问题之一。将抗生素封装在脂质体中是控制这种微生物引起的感染的良好策略。亚胺培南/西司他丁脂质体形式的体外抗铜绿假单胞菌作用评价。通过使用圆盘琼脂扩散技术，鉴定了分离株的抗生素耐药性模式。使用薄层和乙醇注射技术制成纳米脂质体后，将抗生素放入纳米脂质体中。SEM 和 DLS 用于确定封装药物形式和空纳米脂质体的尺寸、形状和 zeta 电位。此外，还使用 ​​FT-IR 光谱研究了纳米脂质体中亚胺培南/西司他丁的封装。在微生物测定实验中，测定了脂质体和游离药物形式的 MIC、MBC 和 MBEC。纳米粒子呈球形，直径范围为30至39 nm，薄层和乙醇注射程序中的EE%分别为97和98。亚胺培南/西司他丁纳米脂质体在3009 cm ^-1和1650 cm ^-1处显示峰，证明了所封装药物的化学结构的热力学稳定性，并验证了纳米脂质体中抗生素的封装。与游离药物形式相比，纳米脂质体在大多数分离株中具有较低的 MIC 和 MBC 值，并且具有更强的消除生物膜形成的能力。结果表明，两种纳米脂质体制备技术对 80% 的分离株更有效，其结果与许多其他研究的结果一致。总体而言，根据 MIC 和 MBC 的评估，我们证明纳米脂质体的抗菌活性高于游离药物形式。药物纳米脂质体技术为如何管理对抗生素耐药的微生物感染提供了良好的未来前景。

图形概要